S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

Adverum Biotechnologies (ADVM) Stock Forecast & Price Target

$0.90
-0.11 (-10.89%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.88
▼
$1.04
50-Day Range
$0.81
▼
$1.26
52-Week Range
$0.53
▼
$2.34
Volume
408,462 shs
Average Volume
226,191 shs
Market Capitalization
$90.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Adverum Biotechnologies Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$3.50
288.85% Upside
High Forecast$6.00
Average Forecast$3.50
Low Forecast$2.00
TypeCurrent Forecast
12/9/22 to 12/9/23		1 Month Ago
11/9/22 to 11/9/23		3 Months Ago
9/10/22 to 9/10/23		1 Year Ago
12/9/21 to 12/9/22
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$3.50$3.40$3.75$3.00
Predicted Upside288.85% Upside177.85% Upside191.39% Upside234.17% Upside
Get Adverum Biotechnologies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.


ADVM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ADVM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Adverum Biotechnologies Stock vs. The Competition

TypeAdverum BiotechnologiesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside288.85% Upside737.03% Upside3,819.11% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/2/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$2.00+106.01%
9/5/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$6.00+229.67%
8/11/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Gataulin
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Buy$2.00 ➝ $4.00+118.58%
3/7/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$2.00+161.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:41 PM ET.












ADVM Price Target - Frequently Asked Questions

What is Adverum Biotechnologies's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Adverum Biotechnologies stock is Buy based on the current 4 buy ratings for ADVM. The average twelve-month price prediction for Adverum Biotechnologies is $3.50 with a high price target of $6.00 and a low price target of $2.00. Learn more on ADVM's analyst rating history.

Do Wall Street analysts like Adverum Biotechnologies more than its competitors?

Analysts like Adverum Biotechnologies more than other Medical companies. The consensus rating for Adverum Biotechnologies is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ADVM compares to other companies.

Does Adverum Biotechnologies's stock price have much upside?

According to analysts, Adverum Biotechnologies's stock has a predicted upside of 159.89% based on their 12-month stock forecasts.

What analysts cover Adverum Biotechnologies?

Adverum Biotechnologies has been rated by Mizuho in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ADVM) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -